ArticleBMC bioinformatics2023
Deep learning-based classification model for GPR151 activator activity prediction.
Article in BMC bioinformatics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 4 citations in OpenAlex.
- Integrated Computer-Aided Drug Design: Advances in GPCR Natural Ligand Discovery.Cell biochemistry and biophysics · 2026Review
- The Orphan Receptor GPR151: Discovery, Expression, and Emerging Biological Significance.ACS chemical neuroscience · 2025Review
- AiGPro: a multi-tasks model for profiling of GPCRs for agonist and antagonist.Journal of cheminformatics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundGPR151 is a kind of protein belonging to G protein-coupled receptor family that is closely associated with a variety of physiological and pathological processes.The potential use of GPR151 as a therapeutic target for the management of metabolic disorders has been demonstrated in several studies, highlighting the demand to explore its activators further. Activity prediction serves as a vital preliminary step in drug discovery, which is both costly and time-consuming. Thus, the development of reliable activity classification model has become an essential way in the process of drug discovery, aiming to enhance the efficiency of virtual screening.
resultsWe propose a learning-based method based on feature extractor and deep neural network to predict the activity of GPR151 activators. We first introduce a new molecular feature extraction algorithm which utilizes the idea of bag-of-words model in natural language to densify the sparse fingerprint vector. Mol2vec method is also used to extract diverse features. Then, we construct three classical feature selection algorithms and three types of deep learning model to enhance the representational capacity of molecules and predict activity label by five different classifiers. We conduct experiments using our own dataset of GPR151 activators. The results demonstrate high classification accuracy and stability, with the optimal model Mol2vec-CNN significantly improving performance across multiple classifiers. The svm classifier achieves the best accuracy of 0.92 and F1 score of 0.76 which indicates promising applications for our method in the field of activity prediction.
conclusionThe results suggest that the experimental design of this study is appropriate and well-conceived. The deep learning-based feature extraction algorithm established in this study outperforms traditional feature selection algorithm for activity prediction. The model developed can be effectively utilized in the pre-screening stage of drug virtual screening.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.